Risk factors for hepatocellular carcinoma recurrence after liver transplantation

Abstract

Liver transplantation (LT) provides an excellent option for the long-term survival of patients with unresectable hepatocellular carcinoma (HCC) based on the Milan criteria. Despite careful selection of patients, HCC may still recur after LT, which represents the most important negative predictor of post-transplant survival. The growing demand for LT in HCC has led to the expansion of patient selection criteria, with a resultant increase in the risk of post-transplant HCC recurrence. Numerous tumor and host factors predict HCC recurrence. The morphological, histological, and serological characteristics of tumors in predicting HCC recurrence have been extensively studied. Furthermore, the type and duration of anticancer response before LT has also been considered a surrogate marker of tumor aggressiveness and is associated with the risk of recurrence. The demographic and clinical characteristics of recipients, as well as the type and duration of exposure to immunosuppressive therapy, represent the main host-related risk factors. Many studies have attempted to describe predictive models for the risk of HCC recurrence, considering evaluable parameters both before and after LT. Although many models have been proposed, relatively few have been externally validated on different patient populations. This paper aims to comprehensively summarize the available data on the predictive factors of HCC recurrence after LT, and to examine and discuss those that have been externally validated.

Keywords

Liver transplantation / hepatocellular carcinoma / tumor recurrence / risk predictive model

References

[1] Forner A,Bruix J.Hepatocellular carcinoma..Lancet2018;391:1301-14

[2] Simonetti RG,Fiorello F,D’Amico G.Hepatocellular carcinoma. A worldwide problem and the major risk factors..Dig Dis Sci1991;36:962-72

[3] Toniutto P,Ferrarese A.Current challenges and future directions for liver transplantation..Liver Int2017;37:317-27

[4] Starzl TE,Vonkaulla KN,Brittain RS.Homotransplantation of the Liver in Humans..Surg Gynecol Obstet1963;117:659-76 PMCID:PMC2634660

[5] Starzl TE,Brettschneider L,Fulginiti VA.Orthotopic homotransplantation of the human liver..Ann Surg1968;168:392-415 PMCID:PMC1387344

[6] Mazzaferro V,Doci R,Pulvirenti A.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis..N Engl J Med1996;334:693-9

[7] Plessier A,Consigny Y,Dondero F.Underestimation of the influence of satellite nodules as a risk factor for post-transplantation recurrence in patients with small hepatocellular carcinoma..Liver Transpl2004;10:S86-90

[8] Escartin A,Bilbao I,Bueno J.Recurrence of hepatocellular carcinoma after liver transplantation..Transplant Proc2007;39:2308-10

[9] Valdivieso A,Gastaca M,Ventoso A.Management of hepatocellular carcinoma recurrence after liver transplantation..Transplant Proc2010;42:660-2

[10] Roayaie S,Sung MW,Miller CM.Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis..Liver Transpl2004;10:534-40

[11] Mazzaferro V,Miceli R,Schiavo M.Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis..Lancet Oncol2009;10:35-43

[12] Al-Ameri AAM,Wen X,Guo H.Systematic review: risk prediction models for recurrence of hepatocellular carcinoma after liver transplantation..Transpl Int2020;33:697-712

[13] Shah SA,McGilvray ID,Levy GA.Does microvascular invasion affect outcomes after liver transplantation for HCC? A histopathological analysis of 155 consecutive explants..J Gastrointest Surg2007;11:464-71 PMCID:PMC1852377

[14] Zhang X,Shen F.Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma..J Gastroenterol Hepatol2018;33:347-54

[15] Jonas S,Steinmuller T,Radke C.Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis..Hepatology2001;33:1080-6

[16] Costentin CE,Zhu AX.Is it time to reconsider the Milan Criteria for selecting patients with hepatocellular carcinoma for deceased-donor liver transplantation?.Hepatology2019;69:1324-36

[17] Herrero JI,Quiroga J,Herraiz M.Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma..Liver Transpl2001;7:631-6

[18] Roayaie S,Emre SH,Sheiner PA.Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters..Ann Surg2002;235:533-9 PMCID:PMC1422469

[19] Kneteman NM,Al Saghier M,Blitz M.Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma..Liver Transpl2004;10:1301-11

[20] Silva M,Berenguer M,Lopez-Andujar R.Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma..Liver Transpl2008;14:1449-60

[21] Fan J,Xu Y,Wu ZQ.Indication of liver transplantation for hepatocellular carcinoma: Shanghai Fudan Criteria..Zhonghua Yi Xue Za Zhi2006;86:1227-31

[22] Fan J,Fu ZR,Xia Q.Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China..J Cancer Res Clin Oncol2009;135:1403-12

[23] Yao FY,Bass NM,Ascher NL.Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging..Am J Transplant2007;7:2587-96

[24] American College of Radiology. Liver Imaging Reporting and Data System (LI-RADS). Available from: https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2017. [Last accessed on 21 Jul 2020]

[25] Lee S,Roh YH,Park MS.Diagnostic performance of CT/MRI Liver imaging reporting and data system v2017 for hepatocellular carcinoma: a systematic review and meta-analysis..Liver Int2020;40:1488-97

[26] Cillo U,Bassanello M,Brolese A.Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma..Ann Surg2004;239:150-9 PMCID:PMC1356206

[27] Sotiropoulos GC,Molmenti E,Nadalin S.Liver transplantation for hepatocellular carcinoma in cirrhosis: is clinical tumor classification before transplantation realistic?.Transplantation2005;79:483-7

[28] Shah SA,McGilvray ID,Cleary SP.Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma..Transplantation2006;81:1633-9

[29] Cuccurullo V,Mazzarella G.Microvascular Invasion in HCC: the molecular imaging perspective..Contrast Media Mol Imaging2018;2018:9487938 PMCID:PMC6193341

[30] Yaprak O,Ertugrul G.Role of pre-transplant 18F-FDG PET/CT in predicting hepatocellular carcinoma recurrence after liver transplantation..World J Gastrointest Oncol2018;10:336-43 PMCID:PMC6198297

[31] Sweeney MJ,Morris HP.Comparative biochemistry hepatomas. Iv. isotope studies of glucose and fructose metabolism in liver tumors of different growth rates..Cancer Res1963;23:995-1002

[32] Torizuka T,Inokuma T,Sasayama S.In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET..J Nucl Med1995;36:1811-7

[33] Yang SH,Lee HW,Cho JY.The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients..Liver Transpl2006;12:1655-60

[34] Lee SD.Role of positron emission tomography/computed tomography in living donor liver transplantation for hepatocellular carcinoma..Hepatobiliary Surg Nutr2016;5:408-14 PMCID:PMC5075823

[35] Kornberg A,Tannapfel A,Krause B.Patients with non-[18 F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation..Liver Transpl2012;18:53-61

[36] Lin CY,Chu LY,Jeng LB.Predictive value of 18F-FDG PET/CT for vascular invasion in patients with hepatocellular carcinoma before liver transplantation..Clin Nucl Med2017;42:e183-e87

[37] Bailly M,Orain I,Ribeiro MJ.18F-FDG PET in liver transplantation setting of hepatocellular carcinoma: predicting histology?.Clin Nucl Med2016;41:e126-9

[38] Ahn SY,Joo I,Lee SJ.Prediction of microvascular invasion of hepatocellular carcinoma using gadoxetic acid-enhanced MR and (18)F-FDG PET/CT..Abdom Imaging2015;40:843-51

[39] Takada Y,Shirabe K,Egawa H.Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: a Japanese multicenter study..J Hepatobiliary Pancreat Sci2017;24:49-57

[40] Lee SD,Kim SK,Park SJ.Clinical Impact of 18F-Fluorodeoxyglucose positron emission tomography/computed tomography in living donor liver transplantation for advanced hepatocellular carcinoma..Transplantation2015;99:2142-9

[41] Citores MJ,de la Fuente S.Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation..World J Hepatol2019;11:50-64 PMCID:PMC6354126

[42] Pommergaard HC,Rosenberg J.Serologic and molecular biomarkers for recurrence of hepatocellular carcinoma after liver transplantation: a systematic review and meta-analysis..Transplant Rev (Orlando)2016;30:171-7

[43] Duvoux C,Decaens T,Badran H.Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria..Gastroenterology2012;143:986-94 e3quiz e14-5

[44] Notarpaolo A,Magistri P,Colledan M.Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC..J Hepatol2017;66:552-9

[45] Hakeem AR,Marangoni G,Prasad KR.Systematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma..Aliment Pharmacol Ther2012;35:987-99

[46] Vibert E,Hoti E,Samuel D.Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor..Am J Transplant2010;10:129-37

[47] Lai Q,Graziadei I,Rossi M.Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation..Liver Transpl2013;19:1108-18

[48] Han K,Barkun JS,Tchervenkov JL.Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation..Can J Gastroenterol2007;21:39-45 PMCID:PMC2656629

[49] Dumitra TC,Metrakos PP,Chaudhury P.Pretransplantation alpha-fetoprotein slope and milan criteria: strong predictors of hepatocellular carcinoma recurrence after transplantation..Transplantation2013;95:228-33

[50] Burra P,Caraceni P,Rendina M.Specific issues concerning the management of patients on the waiting list and after liver transplantation..Liver Int2018;38:1338-62

[51] DuBay D,Sandhu L,Guba M.Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion..Ann Surg2011;253:166-72

[52] Sapisochin G,Laurence JM,Barbas A.The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study..Hepatology2016;64:2077-88

[53] Zheng SS,Wu J,Wang WL.Liver transplantation for hepatocellular carcinoma: Hangzhou experiences..Transplantation2008;85:1726-32

[54] Toso C,Bigam DL,Kneteman NM.Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database..Hepatology2009;49:832-8

[55] Toso C,Hernandez-Alejandro R,Marotta P.Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation..Hepatology2015;62:158-65

[56] Varona MA,Aguirre-Jaime A,Oton E.Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience..Transplant Proc2015;47:84-9

[57] Pinero F,de Ataide EC,Marciano S.Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America..Liver Int2016;36:1657-67

[58] Rhu J,Choi GS,Joh JW.Validation of the alpha-fetoprotein model for hepatocellular carcinoma recurrence after transplantation in an Asian population..Transplantation2018;102:1316-22

[59] Mazzaferro V,Zhou J,De Carlis L.Metroticket 2.0 Model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma..Gastroenterology2018;154:128-39

[60] Fujiyama S,Hashiguchi O.Plasma abnormal prothrombin (des-gamma-carboxy prothrombin) as a marker of hepatocellular carcinoma..Cancer1988;61:1621-8

[61] Shirabe K,Yoshizumi T,Taketomi A.The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin..J Surg Oncol2007;95:235-40

[62] Pote N,Albuquerque M,Belghiti J.Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion..J Hepatol2015;62:848-54

[63] Okuda H,Takatsu K,Hayashi N.Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein alone and those seropositive for des-gamma-carboxy prothrombin alone..J Gastroenterol Hepatol2001;16:1290-6

[64] Hong YM,Yoon KT,Yang KH.Risk factors of early recurrence after curative hepatectomy in hepatocellular carcinoma..Tumour Biol2017;39:1010428317720863

[65] Taketomi A,Soejima Y,Uhciyama H.Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation..Transplantation2009;87:531-7

[66] Takada Y,Ueda M,Haga H.Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria..Dig Dis2007;25:299-302

[67] Fujiki M,Ogura Y,Kaido T.Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma..Am J Transplant2009;9:2362-71

[68] Kaido T,Mori A,Ito T.Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma..Surgery2013;154:1053-60

[69] Soejima Y,Yoshizumi T,Aishima S.Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma..Transplantation2007;83:893-9

[70] Shirabe K,Morita K,Uchiyama H.Comparative evaluation of expanded criteria for patients with hepatocellular carcinoma beyond the Milan criteria undergoing living-related donor liver transplantation..Clin Transplant2011;25:E491-8

[71] Lee JH,Kim HY,Lee DH.Serum tumor markers provide refined prognostication in selecting liver transplantation candidate for hepatocellular carcinoma patients beyond the Milan criteria..Ann Surg2016;263:842-50

[72] Chaiteerakij R,Addissie BD,Harmsen WS.Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation..Liver Transpl2015;21:599-606 PMCID:PMC4490162

[73] Zheng Z,Gao S,Yao J.Prognostic role of C-reactive protein in hepatocellular carcinoma: a systematic review and meta-analysis..Int J Med Sci2013;10:653-64 PMCID:PMC3619114

[74] An HJ,Bae SH,Yoon SK.Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma..Liver Transpl2012;18:1406-14

[75] Kim YK,Lee SD,Park SJ.Pretransplant serum levels of C-reactive protein predict prognoses in patients undergoing liver transplantation for hepatocellular carcinoma..Transplant Proc2015;47:686-93

[76] Halazun KJ,Rana AA,Luyten EJ.Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma..Ann Surg2009;250:141-51

[77] Najjar M,Emond JC.Pretreatment neutrophil-lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma..J Hepatocell Carcinoma2018;5:17-28 PMCID:PMC5779314

[78] Xu ZG,Liu LX,Zhao ZX.The pretransplant neutrophil-lymphocyte ratio as a new prognostic predictor after liver transplantation for hepatocellular cancer: a systematic review and meta-analysis..Biomark Med2018;12:189-99

[79] Lai Q,Larghi Laureiro Z,Ginanni Corradini S.Platelet-to-lymphocyte ratio in the setting of liver transplantation for hepatocellular cancer: a systematic review and meta-analysis..World J Gastroenterol2018;24:1658-65 PMCID:PMC5910549

[80] Han S,Yang JD,Ahn JH.Risk of posttransplant hepatocellular carcinoma recurrence is greater in recipients with higher platelet counts in living donor liver transplantation..Liver Transpl2018;24:44-55

[81] Kusumanto YH,Hospers GA,Mulder NH.Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor..Angiogenesis2003;6:283-7

[82] Bambace NM.The platelet contribution to cancer progression..J Thromb Haemost2011;9:237-49

[83] Gay LJ.Contribution of platelets to tumour metastasis..Nat Rev Cancer2011;11:123-34 PMCID:PMC6894505

[84] Bihari C,Shasthry SM,Bhadoria AS.Platelets contribute to growth and metastasis in hepatocellular carcinoma..APMIS2016;124:776-86

[85] von Felden J.Role of molecular biomarkers in liver transplantation for hepatocellular carcinoma..Liver Transpl2020;26:823-31

[86] Nishida N,Kaido T,Yamao K.Molecular scoring of hepatocellular carcinoma for predicting metastatic recurrence and requirements of systemic chemotherapy..Cancers (Basel)2018;10: PMCID:PMC6210853

[87] Miltiadous O,Hoshida Y,Harrington AN.Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation..J Hepatol2015;63:1368-77

[88] Hoshida Y,Kobayashi M,Brunet JP.Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma..Cancer Res2009;69:7385-92 PMCID:PMC3549578

[89] Villanueva A,Battiston C,Sia D.Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma..Gastroenterology2011;140:1501-12.e2 PMCID:PMC3081971

[90] Dvorchik I,Fiel MI,Marsh JW.Fractional allelic imbalance could allow for the development of an equitable transplant selection policy for patients with hepatocellular carcinoma..Liver Transpl2008;14:443-50

[91] Pagano D,Conaldi PG,Di Francesco F.Role of allelic imbalance in predicting hepatocellular carcinoma (HCC) recurrence risk after liver transplant..Ann Transplant2019;24:223-33 PMCID:PMC6500106

[92] Yang Z,Wu LM,Zhang F.Combination of polymorphisms within the HDAC1 and HDAC3 gene predict tumor recurrence in hepatocellular carcinoma patients that have undergone transplant therapy..Clin Chem Lab Med2010;48:1785-91

[93] Wu LM,Zhou L,Xie HY.Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma..PLoS One2010;5:e14460 PMCID:PMC3012077

[94] Zhang Q,Zhou J,Zhao Q.CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients..Cancer Biol Ther2006;5:808-14

[95] Liese J,Doering C,Herrmann E.A possible role of microRNAs as predictive markers for the recurrence of hepatocellular carcinoma after liver transplantation..Transpl Int2016;29:369-80

[96] Nakano T,Wang CC,Tseng HP.Circulating exosomal miR-92b: Its role for cancer immunoediting and clinical value for prediction of posttransplant hepatocellular carcinoma recurrence..Am J Transplant2019;19:3250-62

[97] Sanchez-Lorencio MI,Saenz L,De La Orden V.Comparison of Two types of liquid biopsies in patients with hepatocellular carcinoma awaiting orthotopic liver transplantation..Transplant Proc2015;47:2639-42

[98] Pavel MC.Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: future directions..World J Gastroenterol2018;24:3626-36 PMCID:PMC6113720

[99] Cillo U,Mazzaferro V,Pinna AD.A multistep, consensus-based approach to organ allocation in liver transplantation: toward a “Blended Principle Model”..Am J Transplant2015;15:2552-61

[100] Clavien PA,Bossuyt PM,Langer B.Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report..Lancet Oncol2012;13:e11-22 PMCID:PMC3417764

[101] Yao FY,Flemming J,Hameed B.Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria..Hepatology2015;61:1968-77 PMCID:PMC4809192

[102] Mehta N,Grab JD.National experience on down-staging of hepatocellular carcinoma before liver transplant: influence of tumor burden, alpha-fetoprotein, and Wait Time..Hepatology2020;71:943-54

[103] Yao FY.Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: where do we stand with tumor down-staging?.Hepatology2016;63:1014-25

[104] Heimbach JK,Finn RS,Abecassis MM.AASLD guidelines for the treatment of hepatocellular carcinoma..Hepatology2018;67:358-80

[105] Bruix J,Sherman M.Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma..Gastroenterology2016;150:835-53

[106] European Association for the Study of the LiverElectronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma..J Hepatol2018;69:182-236

[107] Bryce K.Downstaging for hepatocellular cancer: harm or benefit?.Transl Gastroenterol Hepatol2017;2:106 PMCID:PMC5763034

[108] Mehta N,Yao FY,Toso C.Liver transplantation for hepatocellular carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference..Transplantation2020;104:1136-42

[109] Lencioni R.Modified RECIST (mRECIST) assessment for hepatocellular carcinoma..Semin Liver Dis2010;30:52-60

[110] Cucchetti A,Sposito C,Mosconi C.Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant..J Hepatol2020;73:342-8

[111] O’Malley ME,Sherman M.Outcome of small (10-20 mm) arterial phase-enhancing nodules seen on triphasic liver CT in patients with cirrhosis or chronic liver disease..Am J Gastroenterol2005;100:1523-8

[112] Grasso A,Morisco F,Quaglia A.Liver transplantation and recurrent hepatocellular carcinoma: predictive value of nodule size in a retrospective and explant study..Transplantation2006;81:1532-41

[113] Onaca N,Jennings LW,Klintmalm GB.Improved results of transplantation for hepatocellular carcinoma: a report from the international registry of hepatic tumors in liver transplantation..Liver Transpl2009;15:574-80

[114] Decaens T,Badran H,Durand F.Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma..Liver Int2011;31:792-801

[115] Halazun KJ,Abdelmessih RM,Griesemer AD.Recurrence after liver transplantation for hepatocellular carcinoma: a new MORAL to the story..Ann Surg2017;265:557-64

[116] Mehta N,Harnois DM,Dodge JL.Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant..JAMA Oncol2017;3:493-500 PMCID:PMC5395317

[117] Verna EC,Aggarwal A,Frenette C.Liver transplantation for hepatocellular carcinoma: Management after the transplant..Am J Transplant2020;20:333-47

[118] Goldaracena N,Scalera I,Atenafu EG.Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation..HPB (Oxford)2019;21:731-8

[119] Sapisochin G,Astete S,Davidson D.Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large euro-american series..Ann Surg Oncol2015;22:2286-94

[120] Lo CM,Liu CL,Ng IO.Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma..Br J Surg2007;94:78-86

[121] Vakili K,Cheah YL,Lewis WD.Living donor liver transplantation for hepatocellular carcinoma: Increased recurrence but improved survival..Liver Transpl2009;15:1861-6

[122] Bhangui P,Majno P,Andreani P.Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation..Hepatology2011;53:1570-9

[123] Sandhu L,Guba M,Ghanekar A.Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence..Liver Transpl2012;18:315-22

[124] Xiao GQ,Shen S,Yan LN.Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation..World J Gastroenterol2014;20:10953-9 PMCID:PMC4138476

[125] Park MS,Suh SW,Choi Y.Living-donor liver transplantation associated with higher incidence of hepatocellular carcinoma recurrence than deceased-donor liver transplantation..Transplantation2014;97:71-7

[126] Gu XQ,Teng DH,Zheng H.Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patients..World J Gastroenterol2016;22:2749-59 PMCID:PMC4777997

[127] Yang ZF,Luo Y,Ho DW.Up-regulation of vascular endothelial growth factor (VEGF) in small-for-size liver grafts enhances macrophage activities through VEGF receptor 2-dependent pathway..J Immunol2004;173:2507-15

[128] Man K,Xiao JW,Sun BS.The significance of acute phase small-for-size graft injury on tumor growth and invasiveness after liver transplantation..Ann Surg2008;247:1049-57

[129] Shi JH,Suo ZH.Growth of hepatocellular carcinoma in the regenerating liver..Liver Transpl2011;17:866-74

[130] Kulik L.Living donor liver transplantation for hepatocellular carcinoma..Gastroenterology2004;127:S277-82

[131] Fisher RA,Freise CE,Shearon TH.Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation..Am J Transplant2007;7:1601-8 PMCID:PMC3176596

[132] Grat M,Lewandowski Z,Zieniewicz K.The impact of surgical technique on the results of liver transplantation in patients with hepatocellular carcinoma..Ann Transplant2013;18:448-59

[133] Mangus RS,Vianna RM,Jones DT.Use of the piggyback hepatectomy technique in liver transplant recipients with hepatocellular carcinoma..Transplantation2008;85:1496-9

[134] Khan S,Tan YM,Gunson B.Conventional versus piggyback technique of caval implantation; without extra-corporeal veno-venous bypass. A comparative study..Transpl Int2006;19:795-801

[135] Nagai S,Facciuto M,Abouljoud MS.Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation..Hepatology2015;61:895-904

[136] van der Bilt JD,Nijkamp MW,Veenendaal LM.Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model..Hepatology2005;42:165-75

[137] Man K,Lo CM,Sun BS.Ischemia-reperfusion of small liver remnant promotes liver tumor growth and metastases--activation of cell invasion and migration pathways..Liver Transpl2007;13:1669-77

[138] Ku Y,Shiotani M,Iwasaki T.Stimulation of haematogenous liver metastases by ischaemia-reperfusion in rats..Eur J Surg1999;165:801-7

[139] Gasbarrini A,Di Campli C,Montemagno S.Gender affects reperfusion injury in rat liver..Dig Dis Sci2001;46:1305-12

[140] Burra P,Gitto S.Influence of age and gender before and after liver transplantation..Liver Transpl2013;19:122-34

[141] Brahimi-Horn MC.Harnessing the hypoxia-inducible factor in cancer and ischemic disease..Biochem Pharmacol2007;73:450-7

[142] Axelson H,Ovenberger M,Pahlman S.Hypoxia-induced dedifferentiation of tumor cells--a mechanism behind heterogeneity and aggressiveness of solid tumors..Semin Cell Dev Biol2005;16:554-63

[143] Sharma P,Hussain H,Fontana RJ.Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era..Dig Dis Sci2012;57:806-12 PMCID:PMC3288660

[144] Cameron AM,Yersiz H,Lipshutz GS.Optimal utilization of donor grafts with extended criteria: a single-center experience in over 1000 liver transplants..Ann Surg2006;243:748-53discussion 53-5 PMCID:PMC1570573

[145] Segev DL,Simpkins CE,Nguyen GC.Minimizing risk associated with elderly liver donors by matching to preferred recipients..Hepatology2007;46:1907-18

[146] Tashiro H,Mikuriya Y.Ischemia-reperfusion injury in patients with fatty liver and the clinical impact of steatotic liver on hepatic surgery..Surg Today2014;44:1611-25

[147] Jimenez-Castro MB,Mendes-Braz M,Gracia-Sancho J.Adiponectin and resistin protect steatotic livers undergoing transplantation..J Hepatol2013;59:1208-14

[148] Mathur A,Leone JP,Rojas H.Obesity portends increased morbidity and earlier recurrence following liver transplantation for hepatocellular carcinoma..HPB (Oxford)2013;15:504-10 PMCID:PMC3692019

[149] Saxena NK,Ding X,Marra F.Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells..Cancer Res2007;67:2497-507 PMCID:PMC2925446

[150] Rega G,Demyanets S,Rychli K.Vascular endothelial growth factor is induced by the inflammatory cytokines interleukin-6 and oncostatin m in human adipose tissue in vitro and in murine adipose tissue in vivo..Arterioscler Thromb Vasc Biol2007;27:1587-95

[151] Siegel AB,Wang S,Rodriguez RD.Diabetes, body mass index, and outcomes in hepatocellular carcinoma patients undergoing liver transplantation..Transplantation2012;94:539-43 PMCID:PMC3605709

[152] Martins PN,Pascher A,Frei U.Age and immune response in organ transplantation..Transplantation2005;79:127-32

[153] Watt KD.Keys to long-term care of the liver transplant recipient..Nat Rev Gastroenterol Hepatol2015;12:639-48

[154] Lerut J,Foguenne M.Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression?.Transl Gastroenterol Hepatol2017;2:80 PMCID:PMC5676205

[155] Schnitzbauer AA,Geissler EK.Influence of immunosuppressive drugs on the recurrence of hepatocellular carcinoma after liver transplantation: a gap between basic science and clinical evidence..Transplantation2011;91:1173-6

[156] Liang W,Ling X,Kong Y.Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis..Liver Transpl2012;18:62-9

[157] Geissler EK,Zulke C,Proneth A.Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial..Transplantation2016;100:116-25 PMCID:PMC4683033

[158] Cholongitas E,Rodriguez-Castro KI.Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review..Transpl Int2014;27:1039-49

[159] Vivarelli M,La Barba G,Del Gaudio M.Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence..Ann Surg2008;248:857-62

[160] Rodriguez-Peralvarez M,Naveas MC,Garcia-Caparros C.Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma..J Hepatol2013;59:1193-9

[161] Lerut J.An appraisal of tolerance in liver transplantation..Am J Transplant2006;6:1774-80

[162] Benitez C,Miquel R,Abraldes JG.Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients..Hepatology2013;58:1824-35

[163] Angelico R,Manzia TM.Using a weaning immunosuppression protocol in liver transplantation recipients with hepatocellular carcinoma: a compromise between the risk of recurrence and the risk of rejection?.Transl Gastroenterol Hepatol2017;2:74 PMCID:PMC5639004